Selective internal iliac artery oxaliplatin infusion: Another facultative treatment to unremitting hematuria in stage T4 bladder carcinoma

Objective  

To observe and evaluate the value of utilizing selective internal iliac artery infusion and selective internal iliac artery embolization for the treatment of unremitting gross hematuria of stage T4 bladder carcinoma.     

肌层浸润性膀胱癌保留膀胱术后髂内动脉灌注化疗的临床疗效

目的 评价保留膀胱术后联合髂内动脉介入化疗临床疗效。方法 回顾性分析2008年2月— 2013年8月徐州市肿瘤医院经尿道膀胱肿瘤电切术（TURBT）后辅助全身化疗及髂内动脉介入化疗51例膀胱尿路上皮癌患者,分为髂内动脉化疗组（A组19例）和全身化疗组（B组32例）,比较两组5年累计生存率、膀胱保留率及不良反应发生率的差异,同时采用多元Logistic回归分析影响髂动脉化疗组患者预后的因素。结果 A、B两组患者5年累积生存率分别为56.5% 和53.2%,差异无统计学意义（P=0.18）。A组膀胱保留率为78.9%（15/19）高于B组62.5%（20/32）,差异有统计学意义（P=0.024）。A组患者化疗后并发症发生率低于B组,差异有统计学意义（P=0.036）。相关因素分析显示T2期及单发肿瘤的患者适合于髂内动脉化疗。结论 与GC方案全身化疗相比,保留膀胱术后髂内动脉化疗在保证生存率情况下,具有膀胱保留率高、化疗并发症发生率低等优点,值得临床合理选择运用;影响髂内动脉化疗预后的主要因素有临床分期、病理分级及肿瘤数目。     

肌层浸润性膀胱癌保留膀胱综合治疗的疗效评价研究

目的 评价髂内动脉灌注化疗+经尿道膀胱肿瘤电切术+膀胱内灌注化疗综合治疗肌层浸润性膀胱癌的临床疗效.方法 比较64例采用髂内动脉灌注化疗(吡柔比星40 mg/m2、5-FU 1000 mg/m2、羟喜树碱30 mg/m2)+经尿道膀胱肿瘤电切术+膀胱内灌注化疗(综合治疗组)和62例采用经尿道膀胱肿瘤电切术+膀胱内灌注化疗(对照组)的肌层浸润性膀胱癌(T2N0M0期)患者经治疗后的肿瘤复发/转移率、死亡率及治疗相关不良反应的发生情况.结果 至随访截至日期,综合治疗组的无复发/转移率为93.75%(60/64),明显高于对照组的45.16%(28/62),差异有统计学意义(P=0);转移死亡率为3.13%(2/64),低于对照组的16.13%(10/62),差异有统计学意义(P=0.015);非膀胱癌死亡率为10.94%(7/64),与对照组的12.90%(8/62)相比,差异无统计学意义(P﹥0.05).结论 髂内动脉灌注化疗+经尿道膀胱肿瘤电切术+膀胱内灌注化疗的综合治疗方案,能够降低肌层浸润性膀胱癌(T2N0M0)患者肿瘤复发率和死亡率,不增加非癌性死亡风险,值得进一步探讨.     

髂内动脉化疗联合膀胱局部灌注治疗中晚期膀胱癌

目的：探讨术后髂内动脉介入灌注及栓塞在治疗中晚期浸润忡膀胱癌的疗效。方法：对我院1995年1月～2006年1月32例膀胱部分切除术后，髂内动脉灌注及栓塞联合膀胱灌注化疗治疗的中晚期膀胱癌患者的临床资料进行回顾性分析。结果：32例患者5年生存率为80．77％。术后2年内无因肿瘤进展死亡，仅肿瘤局部复发3例。至随访截止13期，死于术后肿瘤进展共6例。结论：髂内动脉化疗栓塞是中晚期膀胱癌膀胱部分切除术后的一种有效的辅助治疗方法，能明显提高患者的5年生存率。     

132例原发性肝癌灌注化疗及栓塞治疗疗效观察

目的 探讨影响肝动脉灌注化疗＋栓塞治疗疗效的因素。方法 １９９３年１月￣１９９７年１０月,对１３２例不能切除的原发性肝癌行选择性插管灌注化疗及栓塞治疗５９７次,肝动脉灌注化疗＋栓塞者１２２例,单纯灌注化疗１０例。结果 １,２,３年生存率分别为８１．８％、３６．４％和１８．２％,疗效较治疗初期有显著提高。肿瘤分期、栓塞剂及其用量、侧支循环的形成以及肝动脉超选择性插管是影响疗效的主要因素。结论 合理施     

超常规剂量碘油超选择TAE与常规TAE后Ⅱ期肝癌切除-27例手术病理及随访研究

目的评价术前应用超常规剂量碘油超选择TAE与常规TAE治疗原发性肝癌的价值。方法1987年8月～1999年12月12年间27例原发性肝癌分为两组治疗组17例,应用常规导管或球囊导管超选择至肿瘤供血动脉,阻断其血流,使注射碘油时不产生逆流,将全部动脉肿瘤血管、病变周围正常的小动脉及肝实质和门静脉分支栓塞,栓后25天～121天手术切除;对照组10例,应用一般导管,常规剂量的碘油超选或不超选栓塞肿瘤供血动脉,栓后20天～140天手术切除。对两组病人切除的标本均进行了详细的病理学研究,同时对全部病人随访3～8年。结果治疗组17例中11例肿瘤100%坏死,其余6例坏死率为85%～95%,3、5年生存率分别为88.2%(15/17)、45.5%(5/11),3例现生存6～8年;对照组10例中2例肿瘤完全坏死,另8例坏死率为75%～95%,3、5年生存率分别为60.0%(6/10)、14.3%(1/7)。结论术前应用超常规剂量碘油超选择TAE治疗原发性肝癌效果明显好于常规TAE。     

选择性髂内动脉灌注化疗和栓塞治疗宫颈复发癌

本文报道３４例经根治性治疗愈合后盆腔复发的宫颈癌患者，经选择性髂内动脉灌注化疗和栓塞治疗６９次，治疗后１．９例肿瘤缩小，近期有效率５５．９％。结果表明：选择性髂内动脉灌注化疗和栓塞治疗在宫颈复发癌的治疗中是一种有效的、安全的方法。     

卵巢癌术后复发介入化疗疗效分析(附18例临床报告)

目的：总结１８例卵巢癌术后复发患者经介入动脉插管化疗的疗效，并对栓塞剂的应用进行了初步探讨。材料和方法：采用经皮股动脉穿刺双侧髂内动脉选择性插管的方法进行化疗灌注和栓塞。化疗方案为卡铂＋表阿霉素（简称：ＣＡ方案），３例在ＣＡ方案的基础上加用足叶乙甙（ＶＰ－１６），５例同时进行髂内动脉栓塞，所用栓塞材料包括明胶海绵碎块（２例）、顺铂微球（２例）、碘化油（１例）。结果：在１５例可评价疗效的病例中，ＣＲ１例，ＰＲ６例，ＭＲ５例，ＳＤ２例，ＰＤ１例，有效率ＣＲ＋ＰＲ为４６．６％（７／１５）。结论：动脉插管化疗是卵巢癌术后复发较合理的辅助疗法；卡铂＋表阿霉素化疗方案对卵巢癌术后复发有较好疗效；进行髂内动脉栓塞化疗时选用明胶海绵碎块作栓塞剂，副作用较少。     

Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma

OBJECTIVE: This study compared the antitumor effect, adverse effects and survival between transcatheter arterial embolization (TAE) and transcatheter arterial infusion chemotherapy (TAI) in patients with hepatocellular carcinoma (HCC). METHODS: The study population consisted of 168 consecutive patients with advanced HCC treated with transcatheter arterial treatments using cisplatin suspended in lipiodol. Among these, 74 patients were treated with TAE, and the remaining 94 patients were treated with TAI. RESULTS: There were no significant differences in any baseline characteristics except hemoglobin, platelets, albumin, and glutamic pyruvic transaminase. Complete or partial tumor response was achieved in 54 patients (73%) in the TAE group and in 48 patients (51%) in the TAI group (p < 0.01). There were two treatment-related deaths caused by acute hepatic failure and acute renal failure in the TAE group. Nausea and deterioration of serum transaminase after TAE were significantly more severe than after TAI. Median survival time and survival rates at 5 years were 3.1 years and 25% in the TAE group, and 2.5 years and 18% in the TAI group (p = 0.37). CONCLUSION: TAE has a higher antitumor effect than TAI, but does not significantly improve the survival of patients with HCC.     

双侧髂内动脉灌注化疗对宫颈癌根治术后患者恢复的影响

目的探讨在宫颈癌手术治疗中，术中髂内动脉灌注化疗的可行性。方法随机抽取2001年1月～2004年6月期间行宫颈癌根治术30例行术中髂内动脉灌注DDP化疗(A组)，与同期30例未接受术中髂内动脉灌注化疗的患者(B组)对照，分析术后恢复情况。结果两组体温、尿量、消化道反应、肛门排气、骨髓抑制、盆腔引流量、膀胱功能恢复情况等均无明显差异，预防性用药能控制恶心、呕吐等消化道反应。结论双侧髂内动脉术中灌注化疗辅助治疗早期宫颈癌操作简单，副作用小，是一种简单、安全、可行的方法。     

髂内动脉栓塞化疗100例宫颈癌手术中应用

[目的]总结宫颈癌根治术中髂内动脉栓塞化疗的作用.[方法]150例宫颈癌患者随机分组,研究组100例(术中栓塞化疗),对照组50例(术中未栓塞化疗),分析两组3、5、7年生存率、病理类型、术中淋巴转移、切缘阳性与生存率、复发转移率的关系.[结果]研究组3、5、7年生存率分别为99%、94%、87%,对照组为94%、75%、58%.两组比较3年生存率无明显差异(P＞0.05),5、7年生存率有显著差异(P＜0.05).研究组3、5、7年复发率分别为0、5%、11%,对照组3、5、7年复发率分别为16%、24%、30%,两组比较3、5、7年复发转移率均有显著差异(P＜0.05).[结论]宫颈癌手术中进行髂内动脉栓塞化疗,可明显提高生存率,降低局部复发与转移.     

Three Treatment Methods via the Hepatic Artery for Hepatocellular Carcinoma - A Retrospective Study

Background: To evaluate the relative effectiveness of different treatments of hepatocellular carcinoma(HCC) via the hepatic artery. Materials and Methods: The study sample group consisted of 418 patients whowere randomly selected from 2008 to 2012 with a first diagnosis of HCC and treated with transcatheter arterialchemoembolization (TACE) or without (TAE) chemotherapy or transcatheter arterial infusion (TAI). Wecollected data including tumor size preoperative and one month thereafter to compare change in areas acrossthe three groups, along with various laboratory indexes for comparison. Results: The overall average change ofareas was 240.8±72.1 mm2. In the three groups it was 265.0±58.0 mm2 vs. 250.5±51.9 mm2 vs. 123.7±26.2 mm2. Ingroups TACE and TAE values were larger than in group TAI (p<0.01), but the difference between the two wasnot statistically significant (p= 0.191). Additionally, U/L change of aspartate aminotransferase (AST) and alanineaminotransferase (ALT) in groups TACE and TAE was greater than in the TAI cases (24.0±13.5 vs. 20.9±12.1 vs.5.47±8.20 and 25.6±13.5 vs.23.2±12.28 vs.5.48±14.3) on the preoperative day and two days thereafter (p<0.01).Between the two groups there was no significant cariation (p= 0.320 and p= 0.609). However, the AST and ALTrecovered to normal levels one month later on therapy with liver protecting drugs. Conclusion: The groupsTACE and TAE demonstrated more effective reduction of tumor size than group TAI. While lipiodol causedacute liver function damage, this proved reversible.     

超选择髂内动脉插管治疗中晚期卵巢癌

 目的:探讨超选择髂内动脉插管治疗中晚期卵巢癌的疗效及其影响因素。方法:对31例中晚期卵巢癌进行双侧髂内动脉超选择化疗并栓塞83次, 全部病例均经随访。 结果:近期疗效较好, 有效率为77.4%。 结论:超选择髂内动脉插管是治疗中晚期卵巢癌的一种新而有效的方法, 影响疗效的因素有:①导管能否超选择; ②肿瘤的大小、临床分期及血管构型; ③药物及栓塞材料的选择; ①病人的自身情况。     

Selective embolization of internal iliac artery for massive haemorrhage from bladder secondary to carcinoma

Uncontrolled haemorrhage from the urinary bladder secondary to carcinoma can at times be a life-threatening complication. We report a case of recurrent carcinoma of bladder where all the conservative measures for controlling hematuria had failed. Selective embolization of both internal iliac arteries was undertaken which controlled haematuria within 12 hours of the procedure. The procedure had not caused any complication up until the patient was last seen 5 months after the procedure.     

不同剂量碘油肝动脉栓塞术治疗原发性肝癌

目的探讨应用超常规剂量碘油超选择TAE与常规TAE治疗原发性肝癌的疗效,并对其进行比较研究。方法1987年8月～1999年12月12年间276例原发性肝癌被分为两组治疗组167例,应用常规导管或球囊导管超选择至肿瘤供血动脉,阻断其血流,使注射碘油时不产生逆流,将全部动脉肿瘤血管、病变周围正常的细小动脉及肝实质和门静脉分支栓塞;对照组109例,应用一般导管,常规剂量的碘油超选或不超选栓塞肿瘤供血动脉。结果治疗组中,栓塞全部动脉肿瘤血管、病变周围正常的细小动脉及肝实质167例,门静脉分支栓塞109例。1、2、3、4、5年生存率分别为98.8%(165/167)、79.9%(107/134)、48%(47/98)、36.6(26/71)、25.5%(12/47);对照组中,仅栓塞了部分或全部动脉肿瘤血管,1、2、3、4、5年生存率分别为79.9%(87/109)、45.5%(40/88)、21.3%、(13/61)、10.2%(5/49)、3.1%(1/32)。两组病人1、2、3、4、5年生存率经统计学处理有极显著差异(P<0.01-0.001),两组病人均无严重合并症发生。结论应用超常规剂量碘油超选择TAE治疗原发性肝癌效果明显好于常规TAE。     

肝动脉化疗栓塞治疗原发性肝癌并门静脉癌栓的临床研究

目的　探讨肝动脉化疗栓塞治疗原发性肝癌并门静脉癌栓的疗效及其意义。方法　 5 4例原发性肝癌并门静脉癌栓的住院患者 ,按不同的治疗方法分成 3组 :保守治疗组 (A组 10例 ) ,单纯肝动脉灌注 (TAI)组 (B组 18例 ) ;肝动脉灌注加栓塞 (TAI +TAE -LP)组 (C组 2 6例 )。结果　A组中位生存期 2 0个期 ,0 5 ,1,1 5年生存例数分别为 1,0 ,0 ;B组中位生存期 4 0个月 ,0 5 ,1,1 5年生存例数分别为 8,0 ,0 ;C组中位生存期 2 5个月 ,0 5 ,1,1 5年生存例数分别为 14 ,3,1。各组生存例数比较 ,差异有显著性 (P <0 0 5 )结论　原发性肝癌伴门静脉癌栓行肝动脉化疗栓塞可明显提高疗效 ,改善患者生活质量 ,延长生存期 ,其中以TAL +TAE -LP可进一步提高生活质量 ,延长生存期     

Effect of internal iliac artery chemotherapy after transurethral resection of bladder tumor for muscle invasive bladder cancer

Objective： To evaluate the clinical effect of transurethral resection of bladder tumor（TUR-BT） combined with internal iliac artery chemotherapy and intravesical instillation therapy for muscle invasive bladder cancer（MIBC）.
Methods： From February 2007 to April 2014, 62 patients with MIBC were treated with TUR-BT combined with intravesical instillation therapy, with or without internal iliac artery chemotherapy, and the chemotherapy regimen is gemcitabine and cisplatin（GC）. The bladder preservation and survival rate as well as cancer-specific survival（CSS） rate and overall survival（OS） rate of the two groups were compared.
Results： Sixty-two patients were followed-up for 26-102 months with an average of 58.4±3.1 months. Recurrence-free survival（RFS） at 2-year for TUR ＋ GC group and TUR group were 77.8% and 53.8%, respectively. Bladder preserved rate（BPR） at 3-year for TUR ＋ GC group and TUR group were 94.4% and 80.8%. CSS rate at 2-year for TUR ＋ GC group and TUR group were 94.4% and 84.6%. The diseasefree survival（DFS） at 1-year for TUR ＋ GC group and TUR group were 83.3% and 61.5%, and 77.8% and 53.8% for the 2nd year. OS at 2-year for TUR ＋ GC group and TUR group were 88.9% and 92.3%.
Conclusions： TUR-BT and intravesical instillation therapy combined with internal iliac artery chemotherapy for MIBC had a better outcome at RFS, BPR and DFS than the treatment without internal iliac artery chemotherapy, and no difference in OS and CSS.     

髂内动脉术中化疗辅助治疗宫颈癌的临床分析

背景与目的:探讨在宫颈癌根治术中髂内动脉灌注化疗的疗效。材料与方法:回顾性分析1996-01～2003-01、7年间105例行宫颈癌根治术,并于术中进行双侧髂内动脉灌注化疗患者的临床资料(化疗组),并与同期50例根治术中未行灌注化疗患者(对照组)进行比较,比较两组患者术后近期临床疗效、术后复发情况、复发率及生存率情况。结果:化疗组于术后3年内3例盆腔复发,2例远处转移,转移复发率为4.81%;对照组中7例于术后3年半内盆腔复发,1例远处转移,转移复发率为18.00%。对照组复发转移率高于化疗组。2年生存率:化疗组为95.0354%,对照组为83.6237%,前者高于后者;4年生存率:化疗组为95.0354%,对照组为79.4833%,前者高于后者。结论:宫颈癌根治术中选择髂内动脉灌注化疗,可降低宫颈癌根治术后复发转移率及死亡率,有效提高患者生存率。     

髂内动脉结扎灌注或化学栓塞治疗晚期盆腔恶性肿瘤

晚期和（或）转移性盆腔恶性肿瘤治疗，比较困难，往往推动了手术治疗的机会，而且对放疗和全身化疗常无明显效果。本文总结了１９８８年２月至１９９３年１２月对１１例晚期盆腔恶性肿瘤病人进行剖腹髂内动脉结扎插管和经皮髂内动脉插管化疗栓塞治疗，发现对不能手术的晚期盆腔恶性肿瘤，有缓解临床症状，改善生存质量之作用，近期疗效较好。